Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse

NCT07686965 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

191

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia (AML)
Maintenance Treatment
Hematopoetic Stem Cell Transplantation

Interventions

DRUG: Lisaftoclax Plus Azacitidine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China